Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Lbl-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

DMDing MiJSJianming SunTLTongjun Liu

Discussion

Loading...

Member takes

Overview

Trispecific T cell engager demonstrates potent cytotoxicity against multiple myeloma cells, indicating improved therapeutic options for relapsed/refactory patients.

Key Points

  • LBL-076 achieved significant cytotoxicity against myeloma cells, showcasing promise in relapsed refractory multiple myeloma.
  • The trispecific T cell engager effectively activated T cells while minimizing on-target, off-tumor toxicity occurrences.
  • Development utilized the Leadsbody platform, focusing on a 2:1:1 antibody format for optimal efficacy and safety.
  • The dual-targeting approach may transform treatment outcomes for patients experiencing antigen escape or loss.

Cite This Study

Mi et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5e4https://doi.org/10.1182/blood-2025-3302
View Full Paper
Ask AI
Bookmark
Share